# Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

> **NCT06919939** · PHASE2 · RECRUITING · sponsor: **University of Miami** · enrollment: 26 (estimated)

## Conditions studied

- Large B-cell Lymphoma
- Relapse

## Interventions

- **DRUG:** Epcoritamab
- **DRUG:** Loncastuximab Tesirine

## Key facts

- **NCT ID:** NCT06919939
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-07
- **Primary completion:** 2031-01-07
- **Final completion:** 2031-01-07
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06919939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06919939, "Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT06919939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*